EGFR tyrosine-kinase inhibitors (EGFR-TKIs) remain a standard therapy in EGFR-mutant advanced NSCLC.8 Despite the high initial objective response rate (ORR), tumors inevitably become resistant to EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.